Report Overview
Preeclampsia Diagnostics Market Size, Highlights
Preeclampsia Diagnostics Market Size:
The global preeclampsia diagnostics market is expected to grow at a CAGR of 2.60% from US$1.012 billion in 2022 to US$1.211 billion in 2029.
Preeclampsia is a hypertensive problem that creates complex problems in pregnant women by high levels of protein in urine, indicating kidney damage. The growing prevalence of preeclampsia in pregnant women globally is creating a demand for diagnostic tests, thereby boosting the preeclampsia diagnostics market. Moreover, the rising awareness about the risk factors of the complication, coupled with government initiatives and technological advancements for enhanced prediction, is further expected to boost the preeclampsia diagnostics market throughout the forecast period.
Preeclampsia Diagnostics Market Growth Drivers:
- Growing Prevalence of Preeclampsia Cases
The rising number of global preeclampsia cases due to irregular regulation of blood pressure is a major growth driver of the preeclampsia diagnostics market. According to the National Institute of Health, around 50,000 maternal deaths and 500,000 fetal deaths occur each year worldwide due to preeclampsia complications. Moreover, hypertension occurs in 1 in every 12 – 17 pregnancies each year for women aged 20-44 years in the US, as per the CDC estimates. High blood pressure is very common nowadays in pregnancy, which is a defining feature of preeclampsia. Preeclampsia may create problems for women even after pregnancy, showing the need for prevention and the need for preeclampsia diagnostics tests, thereby it is expected to drive the preeclampsia diagnostics market.
- Multiple Risk Factors for Mother and Baby
There are various side effects of preeclampsia both on the mother and the baby, and thus, it is required to treat the preeclampsia, thereby propelling the preeclampsia diagnostics market. It may cause preterm births, which increase breathing and feeding problems, and in rare cases, it may result in maternal and infant health. Babies may suffer from Intrauterine Growth Restriction (IUGR), and various studies have shown that children born with IUGR are more prone to diabetes, congestive heart failure, and hypertension in their adult age. According to the Preeclampsia Foundation, around 15% of the 30 million infants born each year are associated with preeclampsia.
- Government and Other Institutions’ Awareness Program
The government programs to raise awareness about preeclampsia complications are driving the preeclampsia diagnostics market. The California Department of Public Health runs a communication campaign in May as Preeclampsia Awareness Month. Moreover, the Maternal, Child, and Adolescent Health (MCAH) division of the country created a social media presence to increase awareness about signs and symptoms of preeclampsia in several languages, including Arabic, Chinese, English, Farsi, Korean, Spanish Tagalog, and Vietnamese. Additionally, the campaigns by various organizations are also expected to boost the preeclampsia diagnostics market. For instance, the Check Know Share campaign was launched by the Preeclampsia Foundation in May 2020 to urge pregnant women to check their blood pressure, know and understand their numbers, and share with their healthcare provider. This was also the theme of the preeclampsia awareness month of 2020.
- Technological Advancements and Innovation
The technological advancements in the healthcare industry, enhancing the precision of preeclampsia tests, are boosting the preeclampsia diagnostics market. In March 2023, an innovative in-person placental growth factor test was introduced in North Wales, which reduces stillbirths and pre-term deliveries. This test measures PLGF levels in just 15 minutes and enables quick segmenting of pregnant women by risk. Moreover, a new algorithm for predicting preeclampsia and tackling worsening mortality rates was announced by Ascertain and Caire Health (a Joint Venture by Northwell Health and Aegis Ventures). Ascertain’s algorithm showed a 10-15% increase over current predictive standards. The company’s VC also said that preeclampsia is extremely addressable with machine learning.
- Opportunities in the Market
The growing prevalence of hypertension in pregnant women provides a good opportunity for the preeclampsia diagnostics market expansion. Moreover, investment prospects in the healthcare industry provide a major opportunity to enter the preeclampsia diagnostics market. For instance, Mirvie raised $60 million in series B funding for the development of breakthrough devices for preeclampsia tests. The Vision Grant Program by Preeclampsia Foundation provides financial help of up to $25,000 every year to study preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Further, the rising awareness among pregnant women due to various awareness programs and increased accessibility to diagnostic tests is also anticipated to propel the preeclampsia diagnostics market, thereby providing an excellent opportunity for market expansion.
Preeclampsia Diagnostics Market Geographical Outlook:
- North America is an Expected Dominant Market
The North American region is expected to hold a significant share of the global preeclampsia diagnostics market during the forecasted period. Various factors attributed to such a share are rising preeclampsia complications in the region and rising awareness among women to adopt the preeclampsia diagnostics test. For instance, the prevalence rate of preeclampsia has increased by 25% in the last two decades in America, as per the Preeclampsia Foundation. Moreover, the recent technological developments and presence of market leaders such as Quidel Corporation and Prestige Brands Holdings further enhance the scope of the preeclampsia diagnostics market in the region.
Preeclampsia Diagnostics Market Players
- Atlas Medical, founded in 1996, is a supplier of quality diagnostic reagents and kits. The company provides HCG latex kits to detect major hormones in the fields of thyroid and fertility, and HCG test cassettes, individually packaged for pregnant women.
- EKF Diagnostics Holdings PLC focuses on point-of-care testing, central laboratory tests, enzyme manufacturing, and the provision of contract manufacturing. The company offers a range of hemoglobin analyzers to identify women with gestational diabetes and help in managing their condition.
Preeclampsia Diagnostics Market Key Development:
- In January 2024, LabCorp (NYSE: LH), a leading provider of advanced laboratory services worldwide, announced the release of a new blood test, cleared by the FDA, designed for assessing the risk and managing severe preeclampsia, a dangerous condition characterized by high blood pressure during pregnancy and after childbirth. Developed by Thermo Fisher Scientific and recognized as one of TIME Magazine's top inventions of 2023, this innovative test measures two specific angiogenic biomarkers linked to preeclampsia: serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF).
- In May 2023, Thermo Fisher Scientific announced that it had received approval from the US Food and Drug Administration (FDA) for two assays designed to evaluate the risk of developing a severe pregnancy complication known as preeclampsia. The Placental Growth Factor (PlGF) plus and soluble FMS-like tyrosine kinase-1 receptor (sFlt-1) assays can be performed in just 30 minutes using the BRAHMS KRYPTOR chemistry analyzer. These assays are the first and only immunoassays to date to receive breakthrough designation and clearance from the FDA for assessing risk and assisting in the clinical management of preeclampsia, as stated by the company. Preeclampsia, a potentially life-threatening condition characterized by high blood pressure, is the leading cause of maternal and fetal mortality and morbidity globally. Incidence rates for this condition have been rapidly increasing in the United States.
- In May 2022, Metabolomics Diagnostics entered into a partnership with the Preeclampsia Foundation to improve preeclampsia prediction by creating precise and less biased tests. Moreover, the partnership aims to improve maternal health by educating and preventing bad outcomes.
- In June 2021, LifeCell launched screening for both early-onset and late-onset preeclampsia screening in India. The company became the first provider in India to offer screening for early and late-onset. There is an addition of the Sflt-1 biomarker in the screening panel to help in accurate diagnosis even in the third trimester.
Preeclampsia Diagnostics Market Scope:
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2022 | US$1.012 billion |
| Market Size Value in 2029 | US$1.211 billion |
| Growth Rate | CAGR of 2.60% from 2022 to 2029 |
| Study Period | 2019 to 2029 |
| Historical Data | 2019 to 2022 |
| Base Year | 2023 |
| Forecast Period | 2024 – 2029 |
| Forecast Unit (Value) | USD Billion |
| Segments Covered |
|
| Companies Covered | |
| Regions Covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Customization Scope | Free report customization with purchase |
Preeclampsia Diagnostics Market Segmentation:
- By Test Type
- Blood Test
- Urine Test
- Others
- By Products & Services
- Instruments
- Reagents & Consumables
- Services
- By End-User
- Hospitals
- Diagnostic Centers
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others
- Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Thailand
- Others
- North America